Yujing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yujing Li has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Xiongbin Lu
Department of Medical and Molecular Genetics and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
11 shared publications - Xinna Zhang
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA
10 shared publications - Chi Zhang
Department of Biomedical Engineering and Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
8 shared publications - Yuanzhang Fang
Department of Medical and Molecular Genetics
8 shared publications - Xiaoming He
Institue of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University , Shenzhen, Guangdong 518055, China
7 shared publications - Cheng Huang
Shanghai University of Traditional Chinese Medicine
6 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Amendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Open AccessAmendment to Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Open AccessAmendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
- RetractionOpen Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Retraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Park jointly notified the JCI of data falsification in Supplemental Figure 8A and Supplemental Figure 9E and misconduct findings against Xiongbin Lu and Yunhua Liu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
RetractionOpen AccessRetraction for Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Park jointly notified the JCI of data falsification in Supplemental Figure 8A and Supplemental Figure 9E and misconduct findings against Xiongbin Lu and Yunhua Liu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- RetractionOpen Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Park jointly notified the JCI of data falsification in Figures 2B and 6D and misconduct findings against Xiongbin Lu and Hanchen Xu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
RetractionOpen AccessRetraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Park jointly notified the JCI of data falsification in Figures 2B and 6D and misconduct findings against Xiongbin Lu and Hanchen Xu. In accordance with the investigation committee's recommendation, the JCI is retracting this article.
- 22 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (110) , eadr9933
Reprogramming intratumoral T reg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy
Regulatory T cells (T reg cells) represent a primary barrier to the development of effective antitumor immunity. Here, we report that reprogramming T reg cells by shifting the expression of FOXP3 from its full-length isoform (FOXP3 FL ) to a short isoform with exon 2 skipped (FOXP3 dE2 ) promotes CD8 T cell–mediated antitumor immunity. FOXP3 dE2 mRNA expression in triple-negative breast cancer tissue positively correlated with overall patient survival. Mice expressing only the FOXP3 dE2 isoform were resistant to the development of multiple types of tumors. Tumor-infiltrating T reg cells expressing the FOXP3 dE2 isoform exhibited lower immunosuppressive activity and promoted CD8 T cell activation. In addition, we designed a morpholino oligo to induce FOXP3 exon 2 skipping, which similarly enhanced antitumor activity in mouse tumor models and the killing capacity of autologous tumor-infiltrating T cells against patient-derived tumor organoids. Our results suggest that promoting FOXP3 dE2 expression reprograms T reg cells to T helper–like cells, thereby enhancing antitumor immunity.
- 22 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (110) , eadr9933
Reprogramming intratumoral T reg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy
Regulatory T cells (T reg cells) represent a primary barrier to the development of effective antitumor immunity. Here, we report that reprogramming T reg cells by shifting the expression of FOXP3 from its full-length isoform (FOXP3 FL ) to a short isoform with exon 2 skipped (FOXP3 dE2 ) promotes CD8 T cell–mediated antitumor immunity. FOXP3 dE2 mRNA expression in triple-negative breast cancer tissue positively correlated with overall patient survival. Mice expressing only the FOXP3 dE2 isoform were resistant to the development of multiple types of tumors. Tumor-infiltrating T reg cells expressing the FOXP3 dE2 isoform exhibited lower immunosuppressive activity and promoted CD8 T cell activation. In addition, we designed a morpholino oligo to induce FOXP3 exon 2 skipping, which similarly enhanced antitumor activity in mouse tumor models and the killing capacity of autologous tumor-infiltrating T cells against patient-derived tumor organoids. Our results suggest that promoting FOXP3 dE2 expression reprograms T reg cells to T helper–like cells, thereby enhancing antitumor immunity.
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (72) , eabo5407
FOXP3 exon 2 controls T reg stability and autoimmunity
Differing from the mouse Foxp3 gene that encodes only one protein product, human FOXP3 encodes two major isoforms through alternative splicing—a longer isoform (FOXP3 FL) containing all the coding exons and a shorter isoform lacking the amino acids encoded by exon 2 (FOXP3 ΔE2). The two isoforms are naturally expressed in humans, yet their differences in controlling regulatory T cell phenotype and functionality remain unclear. In this study, we show that patients expressing only the shorter isoform fail to maintain self-tolerance and develop immunodeficiency, polyendocrinopathy, and enteropathy X-linked (IPEX) syndrome. Mice with Foxp3 exon 2 deletion have excessive follicular helper T (T FH ) and germinal center B (GC B) cell responses, and develop systemic autoimmune disease with anti-dsDNA and antinuclear autoantibody production, as well as immune complex glomerulonephritis. Despite having normal suppressive function in in vitro assays, regulatory T cells expressing FOXP3 ΔE2 are unstable and sufficient to induce autoimmunity when transferred into Tcrb -deficient mice. Mechanistically, the FOXP3 ΔE2 isoform allows increased expression of selected cytokines, but decreased expression of a set of positive regulators of Foxp3 without altered binding to these gene loci. These findings uncover indispensable functions of the FOXP3 exon 2 region, highlighting a role in regulating a transcriptional program that maintains T reg stability and immune homeostasis.
- 24 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (72) , eabo5407
FOXP3 exon 2 controls T reg stability and autoimmunity
Differing from the mouse Foxp3 gene that encodes only one protein product, human FOXP3 encodes two major isoforms through alternative splicing—a longer isoform (FOXP3 FL) containing all the coding exons and a shorter isoform lacking the amino acids encoded by exon 2 (FOXP3 ΔE2). The two isoforms are naturally expressed in humans, yet their differences in controlling regulatory T cell phenotype and functionality remain unclear. In this study, we show that patients expressing only the shorter isoform fail to maintain self-tolerance and develop immunodeficiency, polyendocrinopathy, and enteropathy X-linked (IPEX) syndrome. Mice with Foxp3 exon 2 deletion have excessive follicular helper T (T FH ) and germinal center B (GC B) cell responses, and develop systemic autoimmune disease with anti-dsDNA and antinuclear autoantibody production, as well as immune complex glomerulonephritis. Despite having normal suppressive function in in vitro assays, regulatory T cells expressing FOXP3 ΔE2 are unstable and sufficient to induce autoimmunity when transferred into Tcrb -deficient mice. Mechanistically, the FOXP3 ΔE2 isoform allows increased expression of selected cytokines, but decreased expression of a set of positive regulators of Foxp3 without altered binding to these gene loci. These findings uncover indispensable functions of the FOXP3 exon 2 region, highlighting a role in regulating a transcriptional program that maintains T reg stability and immune homeostasis.
- Retracted
- 17 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (10)
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.
- 17 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (10)
RetractedAtractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.
- Retracted
- 10 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (580)
RETRACTED: Targeted immunotherapy for HER2-low breast cancer with 17p loss
Trastuzumab conjugated to α-amanitin kills HER2-low breast cancer cells with loss of chromosome 17p and enhances checkpoint blockade therapy.
- 10 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (580)
RetractedRETRACTED: Targeted immunotherapy for HER2-low breast cancer with 17p loss
Trastuzumab conjugated to α-amanitin kills HER2-low breast cancer cells with loss of chromosome 17p and enhances checkpoint blockade therapy.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
- Open Access
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (9)
ST2 as checkpoint target for colorectal cancer immunotherapy
Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (9)
Open AccessST2 as checkpoint target for colorectal cancer immunotherapy
Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.